<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669810</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2014-001476-63</org_study_id>
    <nct_id>NCT02669810</nct_id>
  </id_info>
  <brief_title>EXCELLENT (EXpanded CELL ENdocardiac Transplantation)</brief_title>
  <acronym>EXCELLENT</acronym>
  <official_title>EXpanded CELL ENdocardiac Transplantation (EXCELLENT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellProthera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellProthera</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentric controlled phase I / IIb study evaluating the safety and the efficacy of in&#xD;
      vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process,&#xD;
      and injected in patients with an acute myocardial infarction and a LVEF remaining below 50%&#xD;
      after reperfusion versus standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this phase I/IIb is to evaluate the safety, the tolerance and the first&#xD;
      efficacy trends of intracardiac injection of ProtheraCytes (autologous PB-CD34+ Stem Cells&#xD;
      after automated ex-vivo expansion with the StemXpand machine) in patients with an acute&#xD;
      myocardial infarction and decreased ejection fraction. ProtheraCytes will be reinjected using&#xD;
      a dedicated catheter , thus avoiding open chest surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>6 Months</time_frame>
    <description>Comparison of the proportion of Major Adverse Cardiovascular Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricle End Systolic Volume index (LVESVi)</measure>
    <time_frame>6 months</time_frame>
    <description>The improvement of the Left Ventricle End Systolic Volume index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>PROTHERACYTES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The interventional investigators will perform the ProtheraCytes® cardiac injections using a catheter introduced via the femoral route up to the left ventricle cavity for intraventricular injections (Helix/Biocardia) or a catheter introduced via the femoral / radial route up to coronary arteries for epicardiac injections (BullFrog/Mercator).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated as standard treatment for CHF post - AMI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PROTHERACYTES</intervention_name>
    <description>ProtheraCytes endocardiac injections performed with:&#xD;
the HELIX and Morph catheters (if no Intra Ventricular Thrombus)&#xD;
the BullFrog catheter (if Intra Ventricular Thrombus)</description>
    <arm_group_label>PROTHERACYTES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Treatment for CHF post AMI</intervention_name>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. LV main AMI with or without ST segment elevation and with a detection of rise of&#xD;
             troponin with at least one value 70 times above the upper reference limit.&#xD;
&#xD;
          2. MI reperfused with or without stent implantation within 1 week after first symptoms.&#xD;
             D0 = day of last stent implantation) or; D0 = day of hospital presentation when no&#xD;
             stent implanted.&#xD;
&#xD;
          3. Combination of LVEF &lt; 50% and LV akinetic segment(s) - by echography as per local&#xD;
             practice&#xD;
&#xD;
          4. Age must be ≥ 18 and ≤ 85 years&#xD;
&#xD;
          5. Men and Non-pregnant non-lactating women who take efficacious contraceptive measures&#xD;
             such as oral contraceptive medications or efficacious and permanent intra-uterine&#xD;
             device (drug eluted or not) (IUD) or subcutaneous permanent contraceptive implants or&#xD;
             menopaused women (at least 2 years confirmed menopause) or surgically sterilized&#xD;
             women.&#xD;
&#xD;
          6. Having previously signed a written informed consent prior to any study-specific&#xD;
             procedure&#xD;
&#xD;
          7. LVEF remaining &lt; 50% assessed by cMRI at D8 (± 3)&#xD;
&#xD;
          8. Identification of LV akinetic and non-viable segment(s) by cMRI at D8 (± 3)&#xD;
&#xD;
        Non-inclusion criteria&#xD;
&#xD;
          1. History of CABG surgery&#xD;
&#xD;
          2. History of former significant mitral valve replacement surgery or heart&#xD;
             transplantation.&#xD;
&#xD;
          3. History of severe valve disease: mitral, aortic stenosis / insufficiency.&#xD;
&#xD;
          4. History of non-ischemic dilated cardiomyopathy due to valvular dysfunction, mitral&#xD;
             regurgitation, tachycardia, or myocarditis&#xD;
&#xD;
          5. Aortic stenosis as determined as valve area less than 1 cm2 that prohibits catheter&#xD;
             access to LV&#xD;
&#xD;
          6. Presence of a prosthetic / mechanical aortic or mitral valve or heart constrictive&#xD;
             device.&#xD;
&#xD;
          7. Sepsis&#xD;
&#xD;
          8. Endocarditis&#xD;
&#xD;
          9. Infectious pericarditis&#xD;
&#xD;
         10. Pericardial tamponade&#xD;
&#xD;
         11. Severe peripheral vascular disease precluding femoral and/or radial artery access as&#xD;
             determined at the time of original catheterization.&#xD;
&#xD;
         12. Any condition leading to contraindicated or unexploitable cMRI.&#xD;
&#xD;
         13. History of metallic foreign body in their eye&#xD;
&#xD;
         14. Former or current aortic dissection&#xD;
&#xD;
         15. Inadequate bone marrow function: patient at risk to have Haemoglobin &lt; 10 g/dL or&#xD;
             Platelet count &lt; 100 x 109/L at the time of blood harvest&#xD;
&#xD;
         16. Previous G-CSF or other hematopoietic growth factor administration.&#xD;
&#xD;
         17. Blood transfusion within 3 days before the first G-CSF injection&#xD;
&#xD;
         18. Hepatic failure, history of liver cirrhosis or hepatic severe impairment.&#xD;
&#xD;
         19. Constitutional or acquired coagulopathy&#xD;
&#xD;
         20. Treated chronic renal failure, haemodialysis or renal severe impairment (creatinine&#xD;
             clearance &lt; 30 ml/min).&#xD;
&#xD;
         21. Prior or concomitant malignancies except non-melanoma skin cancer or adequately&#xD;
             treated in situ cervical cancer or previous cancer in complete response without any&#xD;
             treatment in the last 5 years.&#xD;
&#xD;
         22. History of prior mediastinal radiation exposure&#xD;
&#xD;
         23. Serious underlying medical condition at the investigator's discretion, which could&#xD;
             impair the ability of the patient to participate in the trial (e.g. ongoing infection,&#xD;
             active autoimmune disease, Amyotrophic Lateral Sclerosis, Systemic Lupus, Multiple&#xD;
             Sclerosis).&#xD;
&#xD;
         24. Chronic immunomodulatory or cytotoxic drug treatment intake.&#xD;
&#xD;
         25. Active bleeding or major surgery within 1 month.&#xD;
&#xD;
         26. History or current Human immunodeficiency HIV1-2, HTLV1, HTLV2 (according to&#xD;
             2006/17/EC)&#xD;
&#xD;
         27. History or current Hepatitis B (prior vaccination accepted) (according to 2006/17/EC)&#xD;
&#xD;
         28. History or current Hepatitis C (according to 2006/17/EC)&#xD;
&#xD;
         29. Syphilis (according to 2006/17/EC)&#xD;
&#xD;
         30. Active participation in any other clinical trials&#xD;
&#xD;
         31. Current or recent treatment (within two months) with another investigational drug or&#xD;
             procedure.&#xD;
&#xD;
         32. Any other co-existing conditions that will preclude participation in the study or&#xD;
             compromise ability to give informed consent.&#xD;
&#xD;
         33. Impairment of cognitive function. If patient is 75-85 years old (included), score &lt; 24&#xD;
             at Mini Mental State Examination (MMSE)&#xD;
&#xD;
         34. Cardiogenic shock: requirement of i.v. catecholamines or mechanical hemodynamic&#xD;
             support (aortic balloon pump) initiated 24 hours before screening cMRI.&#xD;
&#xD;
         35. History of Splenomegaly&#xD;
&#xD;
         36. History of Phenylketonuria&#xD;
&#xD;
         37. History of iron-Dextran allergy&#xD;
&#xD;
         38. History of murine protein allergy&#xD;
&#xD;
         39. Takotsubo&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Flandrin</last_name>
    <role>Study Director</role>
    <affiliation>CellProthera</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic Flandrin</last_name>
    <phone>0033642743533</phone>
    <email>fflandrin@cellprothera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU BESANCON Hopital Jean Minjoz 3 Boulevard A.Fleming</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MENEVEAU, MD, PhD</last_name>
      <phone>+33.3 81 66 94 34</phone>
      <email>nicolas.meneveau@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DIJON Hôpital François Mitterrand 14 rue Gaffarel</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves COTTIN, MD, PhD</last_name>
      <phone>+33.3 80 29 55 81</phone>
      <email>yves.cottin@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérald Vanzetto, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Lefèvre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier Arnaud-De-Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Roubille, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Levèque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Leroux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Roncalli, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme Roncalli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BIRMINGHAM, Queen Elizabeth Hospital ,Mindelsohn Way,</name>
      <address>
        <city>Edgbaston</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohail KHAN, MD</last_name>
      <phone>+44.121 371 4624</phone>
      <email>Sohail.Khan@uhb.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David New, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds University &amp; Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Greenwood, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital W Smithfield,</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony MATHUR, MD, PhD</last_name>
      <phone>+44 20 3416 5000</phone>
      <email>a.mathur@qmul.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

